PRF Technologies rises as animal study shows pain drug matches approved rival

PRF Technologies

25/06/2026 15:06

Updates
** Shares of biotech firm PRF Technologies PRFX.O rise 30% to $1.83, snapping a four-day losing streak
** Co says experimental pain relief drug PRF-110 matched approved drug Zynrelef in reducing post-surgery pain in animal study
** Says PRF-110 is a long-acting local anesthetic for surgical wounds, aimed at reducing need for opioid painkillers
** PRFX notes that the drug stayed longer in tissue and was absorbed more slowly than Zynrelef, suggesting longer-lasting effect
** Findings come from preclinical study in pigs measuring pain sensitivity after surgery, co says
** Adds that plans further studies to test safety and effectiveness across more types of surgeries
** Including session's move, stock down ~44% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))